Circulating CLL cells from patients treated with ibrutinib present the upregulation of surface IgM (compared to pre-treatment levels), which is not followed by an equal up-regulation of surface IgD levels [186,187,188]. The gene discussed is CD40LG; the disease is B-cell chronic lymphocytic leukemia.